Healthcare Providers and Services
Company Overview of DIATHERIX Laboratories, Inc.
DIATHERIX Laboratories, Inc. provides clinical laboratory services for the detection of infectious disease pathogens. It primarily focuses on infectious disease pathogens associated with respiratory infections and Staphylococcus differentiation, including MRSA and healthcare associated infections. The company offers DxRx, a solution for the manifestation of linking diagnostics to therapeutics. In addition, it develops multi-pathogen panels that enable detection of pathogens and toxins in respiratory, wound, gastrointestinal, ENT, HPV, and sexually transmitted disease infections. The company was incorporated in 2007 and is based in Huntsville, Alabama.
601 Genome Way
Huntsville, AL 35806
Founded in 2007
Key Executives for DIATHERIX Laboratories, Inc.
Chairman and Chief Executive Officer
President and Chief Operating Officer
Compensation as of Fiscal Year 2014.
DIATHERIX Laboratories, Inc. Key Developments
DIATHERIX Laboratories, Inc. Receives Second Research Contract from FDA and HHS
Dec 16 14
DIATHERIX Laboratories, Inc. has been awarded a second federal contract to continue its work in the development of research methodologies designed to support the development of diagnostic tools to detect certain low prevalence pathogens. The contract is a joint award from the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) to support the development of diagnostic devices/platforms to detect high priority pathogens, as classified by the National Institute of Allergy and Infectious Diseases (NIAID). Diatherix's research focuses on three NIAID pathogens: Francisella tularensis, Escherichia coli, and Babesia microti. Though not prevalent in the natural environment, the pathogens are prioritized by NIAID because of the ease with which they can be disseminated or transmitted; the mortality rates and public health impact they can generate; their potential to cause public panic and social disruption; and the special actions that are required for public health preparedness. For instance, F. tularensis has a low infectious dose, is highly virulent, and is easily spread by aerosol; as such, it is classified by the NIAID and the U.S. Department of Homeland Security as a Category A Priority pathogen/biological agent that poses high risk to national security and public health. The low prevalence of these pathogens complicates the development of diagnostic tools to aid in their detection, as sufficient clinical samples may not be available to conduct the clinical sensitivity studies required for Food and Drug Administration (FDA) clearance. To address this regulatory and scientific challenge, the FDA is exploring the use of "spiked" clinical samples special lab samples in which the pathogen being studied is introduced at increased or enriched levels to support sensitivity studies for the evaluation of diagnostic devices.
Luminex Corp. Claims Diatherix's Infringed on Patent
Nov 17 13
Luminex Corp. is claiming that Diatherix, is infringing on its patents for rapid testing of a number of medical conditions. A lawsuit filed by Luminex Corp. argues that Diatherix has infringed on three of its patents that are connected with Luminex’s patented xMAP technology, which the company says is capable of performing at least 500 tests on a single sample. Diatherix and its CEO Frank Grimaud are named in the lawsuit. Efforts to obtain a comment from the company were not immediately successful. In the complaint, Luminex alleges Diatherix and Grimaud were familiar with the Luminex patents. Luminex contends the Diatherix violated at least one claim in each of three U.S. patents. The lawsuit also alleges breach of contract and seeks unspecified damages and an order barring Diatherix and its employees from use of the patents.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries